GlobeNewswire Inc | May 25, 2021 04:05PM EDT

May 25, 2021

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (Adagene) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagenes Co-founder, Chief Executive Officer and Chairman,Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021 and the Goldman Sachs 42nd Annual Global Healthcare Conference to be held June 8-11, 2021.

Details on the presentations can be found below.

Jefferies Virtual Healthcare ConferenceDate: Friday, June 4, 2021Presentation Time: 10:00 AM ETWebcast: Click Here

Goldman Sachs 42nd Annual Global Healthcare Conference Date: Thursday, June 10, 2021 Presentation Time: 5:30 PM ETWebcast: Click Here

About AdageneAdagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagenes highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

Investors Contact:Raymond TamAdagene86-512-8777-3626ir@adagene.com

Bruce MackleLifeSci Advisors646-889-1200bmackle@lifesciadvisors.com

Media Contact:Annie Starr6 Degrees973-768-2170astarr@6degreespr.com